Lipid nanoparticles ... on improving nanoparticle thermostability. An obstacle to the widespread delivery of LNP-mRNA COVID-19 vaccines is the need to keep them stored at very low temperatures ...

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

In drug development many applications are found for lipid-based nanoparticles (Lb-NPs ... nano-formulations described above range from low energy methods in which the thermodynamic, solubility ...

[82] However, the escape of siRNAs from the endosome into the cytosol occurred at low ... nanoparticles in combination with the advantageous effects of various functional lipid components enable ...

In a recent paper by Nikanjam and colleagues, synthetic low-density lipoprotein-like nanoparticles were prepared from commercial lipids and a bifunctional synthetic peptide containing the low ...

These factors directly influence therapeutic efficacy, immunogenicity ... enables inline monitoring of lipid-based nanoparticles and proteins, at very low turbidity levels that were previously ...

A new framework bridges a gap in understanding RNA therapeutics by linking the structure of lipid nanoparticles to immune ...

Encapsulated in lipid nanoparticles (LNPs), siRNA can be delivered ... led to a heterogeneous distribution with regions of high and low siRNA concentration. "This heterogeneity can significantly ...

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought ...

In murine models, the platform demonstrated the ability to deliver gene editing systems precisely to the liver while maintaining a low immunogenicity profile. It also has the potential for repeat ...

The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery. The industry is now poised to exploit the full therapeutic potential ...